Project Details
Description
A Phase 3 Open label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab (Erbitux) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer
| Status | Finished |
|---|---|
| Effective start/end date | 9/1/11 → 9/17/17 |
Funding
- BIOTHERA
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.